ABSTRACT
Background Salmonellosis causes significant morbidity and mortality in Africa. Despite being endemic in Nigeria, information on circulating lineages of invasive Salmonella is sparse.
Methods Salmonella enterica isolated from blood (n=60) and cerebrospinal fluid (CSF, n=3) between 2016 and 2020 from five tertiary hospitals in southwest Nigeria were antimicrobial susceptibility-tested and Illumina-sequenced. Genomes were analysed using publicly-available bioinformatic tools.
Results Isolates and sequence types (STs) from blood were S. Typhi [ST1, n =1 and ST2, n =43] and invasive non-typhoidal Salmonella (iNTS) (S. Enteritidis [ST11, n=7], S. Durham [ST10, n=2], S. Rissen [ST8756, n=2], S. Chester [ST2063, n=1], S. Dublin [ST10, n=1], S. Infantis [ST603, n=1], S. Telelkebir [ST8757, n=1] and S. Typhimurium [ST313, n=1], S. Typhi ST2 (n=2) and S. Adabraka ST8757 (n=1) were recovered from CSF. Most S. Typhi belonged to genotype 3.1.1 (n=44), carried an IncY plasmid and had several antibiotic resistance genes (ARGs) including blaTEM-1 (n=38), aph(6)-Id (n=32), tet(A) (n=33), sul2 (n=32), dfrA14 (n=30) as well as quinolone resistance-conferring gyrA_S83Y SNPs (n=37). All S. Enteritidis harboured aph(3’’)-Ib, blaTEM-1, catA1, dfrA7, sul1, sul2, tet(B) genes, and a single ARG, qnrB19, was detected in S. Telelkebir.. Typhoidal toxins cdtB, pltA and pltB were detected in S. Typhi, Rissen, Chester, and Telelkebir.
Conclusion Most invasive salmonelloses in south west Nigeria are vaccine-preventable infections due to multidrug-resistant, West African dominant Typhi lineage 3.1.1.. Invasive NTS serovars, including some harbouring typhoidal toxin or resistance genes represented a third of the isolates emphasizing the need for better diagnosis and surveillance.
Author Summary Whole genome sequencing of 63 invasive Salmonella from 5 tertiary hospitals in Nigeria revealed multiple serovars including a dominant antibiotic-resistance-gene harbouring S. Typhi 3.1.1 genotype comprising a gyrA_S83Y and IncY plasmid. We also report invasive non-typhoidal Salmonella harbouring typhoidal toxins.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Official Development Assistance (ODA) funding from the National Institute of Health Research https://www.nihr.ac.uk/ (grant number 16_136_111) to DMA and INO and the Wellcome Trust https://wellcome.org/ grant number 206194 to DMA. INO was an African Research Leader supported by the UK Medical Research Council (MRC) https://mrc.ukri.org/ and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement that is also part of the EDCTP2 program supported by the European Union (Award # MR/L00464X/1) and is presently a Calestous Juma Science Leadership Fellow supported by the Bill and Melinda Gates Foundation https://www.gatesfoundation.org/ (Award # INV-036234). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for research using these isolates was obtained from the University of Ibadan/University College Hospital institutional review board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Antimicrobial susceptibility testing data has been included and the figures have been refined. Edits were also made to the text.
Data Availability
All data produced in the present work are contained in the manuscript and its posted supplementary data.
